Data from Phase 2 ACE Study (AMBI) of Quizartinib in Refractory Acute Myeloid Leukemia
SAN DIEGO, June 26, 2013 /PRNewswire/ — Ambit Biosciences Corporation (Nasdaq: AMBI) announced today data from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were featured in multiple presentations at the 18th Congress of the European Hematology Association in Stockholm, Sweden.
Data presented included analyses of patients with relapsed or refractory acute myeloid leukemia (AML) from a Phase 2 clinical trial of quizartinib as monotherapy. In the study, quizartinib was administered orally, once a day, in 28-day treatment cycles until disease progression, elective hematopoietic stem cell transplantation (HSCT) or unacceptable toxicity. Based on the positive data from the Phase 2 clinical trial, as well as ongoing discussions with the Food and Drug Administration (FDA), Ambit is planning to initiate a Phase 3 clinical trial in FLT3-ITD positive patients with relapsed or refractory AML in early 2014.
Data Presentations
High Response Rate and Bridging to Hematopoietic Stem Cell Transplantation With Quizartinib (AC220) in Patients With FLT3-ITD– Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)
Mark J. Levis, M.D., Ph.D., Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Md.
Data from 136 FLT3-ITD positive patients, aged 18 years or older, with either relapsed disease or who were refractory to second-line chemotherapy or HSCT, were presented. Of the patients treated, 35 percent were successfully bridged to a potentially curative HSCT, with the greatest proportion receiving a HSCT after achieving a CRi (complete remission with incomplete hematologic recovery) with quizartinib. Additionally, 33 percent of patients who were bridged to HCST after achieving a CRi were still alive after one year, with multiple patients alive after more than two years.
Additional key findings presented include:
- Forty-six percent of FLT3-ITD positive patients achieved a composite complete response (CRc: complete remission (CR) + complete remission with incomplete platelet recovery (CRp) + complete remission with incomplete hematologic recovery (CRi)), including five percent of patients who achieved either a CR or CRp
- Median overall survival for the 47 FLT3-ITD positive patients who were bridged to a subsequent HSCT was 34.1 weeks, compared to 24.1 weeks for the 56 patients who achieved either a CRc or PR but did not undergo a subsequent HSCT
- Median overall survival for the 33 FLT3-ITD positive patients who did not achieve at least a PR to quizartinib and did not undergo a subsequent HSCT was 8.9 weeks
- Twenty percent (27/136) FLT3-ITD positive patients remained alive for more than 12 months and were classified as long-term survivors
- All but one of the long-term survivors achieved at least a PR to quizartinib, with 63 percent (17/27) proceeding to a HSCT after quizartinib
- Ten of the 27 long-term survivors did not undergo a subsequent HSCT and had a median treatment duration of 53.5 weeks
- Quizartinib was generally well tolerated with manageable toxicity which included a grade 3 QTcF prolongation of 20 percent and no grade 4 QTcF prolongation events
Efficacy and Safety of Quizartinib (AC220) in Patients Age ≥60 Years with FLT3-ITD Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)
Hartmut Dohner, M.D., Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
Data from 110 FLT3-ITD positive patients, aged 60 years or older, who relapsed within one year or were refractory to first-line therapy were presented. Of the patients treated, 57 percent achieved a CRc, with seven percent having either a CR or CRp, with a median survival of 25.3 weeks. Additionally, 16 patients (15 percent) remained alive for more than 12 months and were classified as long-term survivors.
Additional key findings presented include:
- Of the 104 FLT3-ITD positive patients who lived at least 28 days to be assessed for response, the median overall survival for the 84 patients who achieved either a CRc or partial response (PR) to quizartinib is 31.1 weeks, compared to 11.8 weeks for the 20 patients who did not achieve at least a PR to quizartinib
- Median overall survival was 25.3 weeks for all patients, with a median of 22.7 weeks for patients age 70 years or older
- All patients who were long-term survivors achieved either a CRc or PR to quizartinib, with 52.1 weeks as median duration of treatment
- Quizartinib was generally well tolerated, with a 30-day mortality rate of five percent
About Quizartinib
Quizartinib (AC220) is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently under evaluation in multiple ongoing studies, which include a Phase 2b clinical trial as monotherapy treatment for adult patients with FLT3-ITD positive relapsed or refractory AML and two Phase 1 studies in a combination treatment regimen with chemotherapy, and as a maintenance therapy following transplant, respectively.
On March 12, 2013, Ambit and Astellas Pharma Inc., announced that their collaboration for the joint development and commercialization of quizartinib will terminate effective September 3, 2013, at which time Ambit will exclusively own worldwide rights to quizartinib and any follow-on compounds. The companies are working on the transition of the current development activities to Ambit.
About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit’s lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit’s clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit’s preclinical portfolio includes a proprietary CSF1R inhibitor program.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Ambit’s expectations regarding future development and therapeutic potential of Ambit’s lead drug candidate and other programs. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ambit’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Ambit’s programs are described in additional detail in Ambit’s SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ambit undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contacts:
Ian Stone or David Schull (Media)
Russo Partners
(619) 308-6541
(212) 845-4271
ian.stone@russopartnersllc.com
david.schull@russopartnersllc.com
Robert Flamm, Ph.D. (Investor)
Russo Partners
(212) 845-4226
robert.flamm@russopartnersllc.com
TraderPower Featured Companies
- Astrotech Corp. (NASDAQ: ASTC)
- Cepton Inc. (NASDAQ: CPTN)
- Clene Inc. (NASDAQ: CLNN)
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
- Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)
- Freight Technologies Inc. (NASDAQ: FRGT)
- InMed Pharmaceuticals Inc. (NASDAQ: INM)
- Lexaria Bioscience Corp. (NASDAQ: LEXX)
- Mullen Automotive Inc. (NASDAQ: MULN)
- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)
Top Small Cap Market News
- $FNGR InvestorNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) Announces Agreements to Add Charging Terminal Access for Users of Growing Da Ge App
- $FRGT InvestorNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Appointed as Solave’s Logistics Solutions Provider for Cross-Border Operations
- $PXMD InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) in Process of Responding to Emergency Request for IV Suramin from African Health Ministry
- $CLNN InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference
- $RFLXF Malaysian Company to Transform Agricultural Waste into Graphite in Nevada
- $FNICF Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) Sees Great Potential Across its Saskatchewan Nickel Projects
- $CIPI Green-Energy Projects Face Financing Woes Amid High Interest Rates
- $LGVN New Study Shows Social Isolation, Frailty Worsen Health Risks for Aging People
- $LGVN InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Exercise Warrants for ~$6.2M
- $SOBR InvestorNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) Inks Deal with Four-Facility Behavioral Health Provider in Florida
- $APAAF InvestorNewsBreaks – Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) (FSE: A0I0) Files NI 43-101 Technical Report for Goiás-Based PCH Ionic Adsorption Clay Project
Recent Posts
- $APAAF InvestorNewsBreaks – Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) (FSE: A0I0) Files NI 43-101 Technical Report for Goiás-Based PCH Ionic Adsorption Clay Project
- $SOBR InvestorNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) Inks Deal with Four-Facility Behavioral Health Provider in Florida
- $LGVN InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Exercise Warrants for ~$6.2M
- $LGVN New Study Shows Social Isolation, Frailty Worsen Health Risks for Aging People
- $CIPI Green-Energy Projects Face Financing Woes Amid High Interest Rates
- $FNICF Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) Sees Great Potential Across its Saskatchewan Nickel Projects
- $RFLXF Malaysian Company to Transform Agricultural Waste into Graphite in Nevada
- $CLNN InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference
Recent Comments
Archives
- April 2024
- January 2023
- June 2022
- December 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009